Sign In
Buy GLP
$48.45
-0.81 (-1.64%)
At Close: Jun 03, 2026
Eli Lilly Soars, Novo Nordisk Plummets On GLP/Obesity Updates - Here's What To Do
02:26pm, Wednesday, 04'th Feb 2026
Eli Lilly and Company defies valuation skeptics, posting 45% revenue growth and 96% EPS growth in 2025, with 2026 guidance projecting $80–83 billion in revenue and $33.5–35 EPS. LLY's manufacturin
Eli Lilly Soared by 39% in 2025, but Here's Another Healthcare Stock to Buy in 2026
11:20am, Wednesday, 04'th Feb 2026
Eli Lilly has leading products in the GLP-1 space, with plans to bring pill versions of its weight loss shots to market. Pfizer is playing catch-up in the GLP-1 space, but it has a long history of inn
Eli Lilly Proves Its GLP-1 Dominance Again, Raising My Price Target
10:26am, Wednesday, 04'th Feb 2026
Eli Lilly delivered robust Q4 results, with revenue up 43% YoY and EPS beating consensus by $0.61. LLY's 2026 guidance calls for $80–83B revenue and $33.50–35 non-GAAP EPS, outpacing consensus and
Novo Nordisk CEO on 2026 Forecast and GLP-1 Pricing
02:39pm, Tuesday, 03'rd Feb 2026
Novo Nordisk CEO Mike Doustdar discusses the company's updated 2026 sales guidance, forecasting a decline of 5 to 13% at constant exchange rates. Doustdar highlights the strong uptake of Novo Nordisk'
Global Partners Declares Fourth-Quarter 2025 Cash Distribution of $0.7600 on Common Units
08:30am, Friday, 30'th Jan 2026
WALTHAM, Mass.--(BUSINESS WIRE)--Global Partners LP (NYSE: GLP) (“Global Partners” or the “Partnership”) today announced that the Board of Directors of its general partner, Global GP LLC, has
VANCOUVER, BC / ACCESS Newswire / January 29, 2026 / LIR Life Sciences Corp. (CSE:SKNY)(OTC PINK:BBCMF)(Frankfurt:N790, WKN:A41QA9) ("LIR" or the "Company")is pleased to announce positive interim resu
Revita-treated patients experienced sustained weight maintenance, improved cardiometabolic profile, and reduced food cravings at 6 months compared with sham, with continued excellent safety and tolera
Missed Out on Eli Lilly? This GLP-1 Stock Could Be a Bargain Buy.
08:30pm, Wednesday, 28'th Jan 2026
Eli Lilly's stock trades at more than 30 times forward earnings, which is a steep price to pay right now. Amgen is a much cheaper option by comparison.
This top stock-picker spotted Nvidia and GLP-1s early — and made over 200%. Here's what he's buying now.
07:50am, Wednesday, 28'th Jan 2026
Citrini Research founder James Van Geelen identifies potential big money trends and stakes his claim far ahead of the crowd.
Jupiter Neurosciences Expands Nugevia™ Addressable Market with Focus on GLP-1 Users
06:00am, Wednesday, 28'th Jan 2026
Nugevia ™ supports metabolic, mitochondrial, and neuroinflammatory biology impacted by GLP-1-driven weight loss
Genentech Announces Positive Phase II Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People Living With Obesity
01:10am, Tuesday, 27'th Jan 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline results from CT388-103, a Phase II clinical trial of
Cal-Maine Foods: Zero Debt, Massive Cash Position, And Ready For GLP-1 Tailwinds
05:32am, Saturday, 24'th Jan 2026
Cal-Maine Foods earns a reiterated buy rating, driven by rapid expansion into prepared foods and a strong, debt-free balance sheet. Prepared food sales surged 586.4% in Q2'FY26, backed by significant
Should You Forget Eli Lilly and Buy These Unstoppable Stocks Instead?
12:45pm, Friday, 23'rd Jan 2026
Eli Lilly is at the forefront of the GLP-1 weight loss drug market. The company's leading position is already being tested by Novo Nordisk's GLP-1 weight loss pill.
Novo's 500% Pill Pop: Wegovy Just Obliterated Every GLP-1 Launch Record
09:12am, Friday, 23'rd Jan 2026
Novo Nordisk A/S' (NYSE: NVO) weight-loss revolution just swallowed a record. In just its second week on the market, Novo Nordisk's oral Wegovy pill hit 20,371 prescriptions, up from 4,289 in week one
Healthy Returns: Structure Therapeutics CEO on its obesity pill, combinations and future of GLP-1s
10:05am, Wednesday, 21'st Jan 2026
Structure Therapeutics CEO Ray Stevens talked about the biotech's path forward and his expectations for the future of the booming GLP-1 space.
